Systemic Lupus Erythematosus: Clinical Trials

305 completed, 129 unknown, 116 recruiting, 51 terminated. 167 Phase 1, 164 Phase 2, 117 Not applicable, 72 Phase 3, 35 Phase 4.

By phase and status

Phase	Trials	Status
Phase 1	167	Completed 70, Recruiting 43, Not yet recruiting 12, Terminated 10, Unknown 10, Withdrawn 10, Active not recruiting 8, Enrolling by invitation 3, Suspended 1
Phase 2	164	Completed 85, Recruiting 23, Terminated 18, Unknown 16, Active not recruiting 10, Withdrawn 6, Not yet recruiting 5, Enrolling by invitation 1
Not applicable	117	Completed 57, Unknown 26, Recruiting 12, Active not recruiting 7, Terminated 7, Not yet recruiting 4, Withdrawn 3, Enrolling by invitation 1
Phase 3	72	Completed 27, Terminated 13, Unknown 12, Active not recruiting 8, Recruiting 7, Withdrawn 3, Enrolling by invitation 1, Not yet recruiting 1
Phase 4	35	Completed 18, Unknown 8, Recruiting 3, Withdrawn 3, Active not recruiting 2, Terminated 1
Early Phase 1	17	Recruiting 6, Unknown 3, Completed 2, Not yet recruiting 2, Terminated 2, Suspended 1, Withdrawn 1

Follow Systemic Lupus Erythematosus: new trials by email Literature Review of Systemic Lupus Erythematosus trials Research Report on Systemic Lupus Erythematosus

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP) CB-010 - Systemic Lupus Erythematosus, Lupus	Phase 1	Withdrawn	Caribou Biosciences, Inc.		2027-12-01	2025-09-19
Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases HN2302 Injection - Autoimmune Disease, Systemic Lupus Erythematosus	Phase 1	Not yet recruiting	Shenzhen MagicRNA Biotechnology Co., Ltd	12	2026-12-31	2026-08-12
Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers Deucravacitinib - Systemic Lupus Erythematosus, Sjögren's Disease	Phase 3	Not yet recruiting	Bristol-Myers Squibb	2300	2026-12-31	2026-09-03
A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases PF-08154225 - Systemic Lupus Erythematosus, Rheumatoid Arthritis	Phase 1 / Phase 2	Not yet recruiting	Pfizer	54	2026-11-19	2026-10-01
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases BMS-986553 - Systemic Lupus Erythematosus, Sjögren's Disease	Phase 1	Not yet recruiting	Bristol-Myers Squibb	60	2026-10-30	2026-10-14
Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV) Anifrolumab: SC formulation via AI, Anifrolumab: IV formulation, Anifrolumab: SC formulation via aPFS - Systemic Lupus Erythematosus	Phase 1	Not yet recruiting	AstraZeneca	92	2026-10-30	2026-07-07
Serum MPO-DNA Complexes as a Biomarker of Disease Activity in Systemic Lupus Erythematosus Systemic Lupus Erythematosus, Lupus Nephritis		Not yet recruiting	Assiut University	90	2026-10-01	2026-09-08
Ocular Surface Changes and Meibomian Gland Dysfunction in Rheumatologic Patients Meibomian Gland Dysfunction, Dry Eye Syndromes		Not yet recruiting	Assiut University	150	2026-10-01	2026-09-09
Saphnelo Use in Females of Child-bearing Potential Anifrolumab - Systemic Lupus Erythematosus		Not yet recruiting	AstraZeneca	26000000	2026-10-01	2026-02-25
SNC116 Therapy for Refractory Systemic Lupus Erythematosus SNC116 - Systemic Lupus Erythematosus	Early Phase 1	Not yet recruiting	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	28	2026-10-01	2026-09-18
Subclinical Gastrointestinal Involvement in Juvenile Systemic Lupus Erythematosus Systemic Lupus Erythematosus, Gastrointestinal Diseases		Not yet recruiting	Assiut University	60	2026-09-30	2026-10-05
A Trial in Healthy Adult Participants and Adults With Autoimmune Disease to Test How HBM7020 is Tolerated and Absorbed in the Body HBM7020 - Rheumatoid Arthritis, Systemic Lupus Erythematosus	Phase 1	Recruiting	Otsuka Pharmaceutical Development & Commercialization, Inc.	63	2026-09-24	2026-10-13
Diastolic Dysfunction and Inflammatory Biomarkers in Lupus Nephritis Lupus Nephritis, Diastolic Dysfunction		Not yet recruiting	Assiut University	90	2026-09-20	2026-09-24
HEALTH Home Urinalysis Testing Home Urine Testing - Systemic Lupus Erythematosus	Not applicable	Recruiting	NYU Langone Health	160	2026-09-08	2026-09-16
Safety and Efficacy of ONT01 in Lupus ONT01 is a small molecule CD11b modulator. - Lupus Nephritis (LN), Lupus Nephritis - WHO Class III	Early Phase 1	Recruiting	Hospital for Special Surgery, New York	61	2026-09-04	2025-11-20
A Study of ATG-201 in Adult Participants With Autoimmune Diseases ATG-201 - Systemic Lupus Erythematosus, Systemic Sclerosis (SSc)	Phase 1	Not yet recruiting	Antengene Biologics Limited	149	2026-09-01	2026-09-21
A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus Anifrolumab + APFS - Systemic Lupus Erythematosus	Phase 2	Recruiting	AstraZeneca	24	2026-08-31	2026-09-22
A Study to Test CRT-402 in Refractory Autoimmune Disease CRT-402 - Autoimmune Diseases, Systemic Lupus Erythematosus	Phase 1 / Phase 2	Recruiting	Myeloid Therapeutics	34	2026-08-26	2026-10-22
SII and SIRI as Prognostic Biomarkers in Lupus Nephritis Lupus Nephritis, Systemic Lupus Erythematosus		Not yet recruiting	Assiut University	100	2026-08-19	2026-08-24
A Study of QLS2404 Injection in Healthy Participants and Participants With Rheumatic Autoimmune Diseases Ia:QLS2404 very low dose, Ia:QLS2404 low dose, Ia:QLS2404 middle dose - Systemic Lupus Erythematosus, Primary Sjögren's Syndrome	Phase 1	Not yet recruiting	Qilu Pharmaceutical Co., Ltd.	64	2026-08-11	2026-08-07

Showing 20 of 711. Sign in to see all of them.

Narrower conditions

Lupus Erythematosus, Systemic (711)  ·  Arthritis, Rheumatoid (75)  ·  Autoimmune Diseases (74)  ·  Scleroderma, Systemic (56)  ·  Lupus Nephritis (47)  ·  Sjogren's Syndrome (39)  ·  Myositis (31)  ·  Immune System Diseases (25)  ·  Arthritis (24)  ·  Connective Tissue Diseases (24)  ·  Arthritis, Psoriatic (18)  ·  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (17)  ·  Spondylitis, Ankylosing (15)  ·  Dermatomyositis (14)  ·  Antiphospholipid Syndrome (13)

Broader conditions

Skin and Connective Tissue Diseases (711)  ·  Connective Tissue Diseases (687)  ·  Immune System Diseases (686)  ·  Autoimmune Diseases (637)  ·  Musculoskeletal Diseases (139)  ·  Joint Diseases (116)  ·  Rheumatic Diseases (101)  ·  Skin Diseases (98)  ·  Arthritis (94)  ·  Nervous System Diseases (65)  ·  Pathological Conditions, Signs and Symptoms (64)  ·  Urogenital Diseases (63)  ·  Female Urogenital Diseases and Pregnancy Complications (61)  ·  Female Urogenital Diseases (58)  ·  Male Urogenital Diseases (58)

Interventions

belimumab (38)  ·  Cyclophosphamide (19)  ·  Blood Specimen Collection (18)  ·  anifrolumab (16)  ·  Standard of Care (15)  ·  Mycophenolic Acid (12)  ·  epratuzumab (12)  ·  Interleukin-2 (10)  ·  fludarabine (10)  ·  Prednisone (9)  ·  Rituximab (8)  ·  deucravacitinib (8)  ·  telitacicept (8)  ·  Adrenal Cortex Hormones (7)  ·  Exercise (7)

Sponsors

GlaxoSmithKline (29)  ·  AstraZeneca (25)  ·  Assiut University (23)  ·  Amgen (12)  ·  Bristol-Myers Squibb (12)  ·  Duke University (11)  ·  UCB Pharma (11)  ·  National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (10)  ·  Sohag University (10)  ·  Assistance Publique - Hôpitaux de Paris (9)  ·  Eli Lilly and Company (9)  ·  Medical University of South Carolina (8)  ·  NYU Langone Health (8)  ·  National Center for Research Resources (NCRR) (8)  ·  Oklahoma Medical Research Foundation (8)

Countries

United States (308)  ·  China (136)  ·  France (101)  ·  Spain (86)  ·  Germany (72)  ·  Poland (72)  ·  Mexico (67)  ·  Canada (61)  ·  Brazil (60)  ·  Taiwan (57)  ·  Argentina (56)  ·  United Kingdom (56)  ·  Italy (52)  ·  Japan (50)  ·  South Korea (43)

Top investigators

Sarfaraz A Hasni, M.D. (5)  ·  Qiubai Li, Professor (4)  ·  Richard Burt, MD (4)  ·  Rosalind Ramsey-Goldman (4)

Results publications

PMID 33687069, PMID 34628605, PMID 34741731, PMID 34531304, PMID 39115551, PMID 39208825, PMID 38216728, PMID 38724182, PMID 38775637, PMID 31302695, PMID 31660791, PMID 33568389, PMID 37228028, PMID 22275291, PMID 22337213, PMID 23213069, PMID 23524886, PMID 23754628, PMID 25396065, PMID 25777546, PMID 25988278, PMID 26138472, PMID 26290435, PMID 27099766, PMID 27220348, PMID 27598855, PMID 27723281, PMID 28925994, PMID 29045736, PMID 29381843, PMID 29409143, PMID 29699792, PMID 31537547, PMID 31790472, PMID 32918459, PMID 33830377, PMID 34347960, PMID 35302581, PMID 35947992, PMID 36109639, PMID 38258369, PMID 38676311, PMID 40256631, PMID 40305472, PMID 40465397, PMID 40920289, PMID 42309556, PMID 42660739, PMID 10513806, PMID 10743805

NIH funding

2023 (18), 2017 (6), 2019 (5), 2025 (5), 2014 (4), 2016 (4), 2018 (4), 2008 (3), 2015 (2), U01AR042540 (2), 2009 (1), K01AR060026 (1), K08CA237619 (1), K23AR078177 (1), KL2TR002554 (1)